Featured Research

from universities, journals, and other organizations

Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack

Date:
May 27, 2011
Source:
European League Against Rheumatism
Summary:
Following a first time myocardial infarction (MI or heart attack) patients with rheumatoid arthritis (RA) were significantly less likely to have been prescribed standard post-MI treatments than healthy controls, according to new data. The authors of the study hypothesize that clinicians may find that treatment of RA patients after a heart attack is more challenging than in healthy individuals.

Following a first time myocardial infarction (MI or heart attack) patients with rheumatoid arthritis (RA) were significantly less likely to have been prescribed standard post-MI treatments than healthy controls, according to data presented at the EULAR 2011 Annual Congress. The authors of the study hypothesize that clinicians may find that treatment of RA patients after a heart attack is more challenging than in healthy individuals.

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients. These finding remained relatively unchanged at 180 days, further highlighting differences between the two groups, with a high number being prescribed the current standards of care within the 180 day period (statins 80%, betablockers 82%, clopidogrel 70%, aspirin 79%) in general.

"Previous research has established that RA patients have an increased risk of cardiovascular disease (CVD). The results of our study suggest that CVD may be under treated in these patients, due to concerns regarding the use of multiple medications or patient compliance," said Dr. Jesper Lindhardsen of the Gentofte University Hospital in Copenhagen, Denmark. "Clinicians may find post-MI treatment in RA patients more complicated which would explain the lower propensity towards prescribing treatment; however this may be increasing the CVD burden seen in RA patients. Additional research is required in this area to establish whether further education is needed."

In the study, researchers identified 98,454 patients (39.4% female), who had suffered an MI for the first time, using the Danish National nationwide individual level registers, which included pharmacy records. Researchers examined 1,113 RA patient's prescriptions (62.5% female) between their first MI and 30 and 180 days following, allowing them to determine whether standard MI treatments had been prescribed or not. Odds ratios were calculated to determine the influence of RA, and were obtained using the statistical tool multivariate logistic regression modelling which included gender, age, co-morbidity and income.

Results of a separate study show that duration of RA doesn't further impact on CV risk over time

Results of one further study investigating the risk of CVD in RA patients, demonstrated that duration of RA did not increase the CVD risk over time. Previous studies have suggested that a number of factors may contribute to RA patients developing CVD such as chronic systemic inflammation or adverse effects associated with RA treatments. However the findings in this study showed no difference in the risk of CVD between patients who had suffered with RA for less or more than 10 years.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack." ScienceDaily. ScienceDaily, 27 May 2011. <www.sciencedaily.com/releases/2011/05/110527075914.htm>.
European League Against Rheumatism. (2011, May 27). Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/05/110527075914.htm
European League Against Rheumatism. "Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack." ScienceDaily. www.sciencedaily.com/releases/2011/05/110527075914.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins